Highlight
- Unopposed estrogen significantly increases risk of endometrial hyperplasia compared to placebo and combined regimens.
- Continuous combined estrogen–progestogen appears protective against hyperplasia within one year.
- Sequential combined regimens may increase short-term hyperplasia risk over placebo.
- Evidence for impact on endometrial cancer remains inconclusive due to rare events and limited power.
Background
